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Abstract 
 
Rationale: Altered lipid metabolism has been reported in severe Obstructive Sleep 
Apnoea (OSA) and may be related to the development of cardiovascular disease. 
Continuous Positive Airway Pressure (CPAP) treatment for 8 weeks leads to 
improvements in postprandial triglycerides and total cholesterol. Intermittent 
episodes of hypoxia and re-oxygenation occur in OSA and have been linked to the 
formation of reactive oxygen species and increased oxidative stress and 
inflammation. We investigated the effect of CPAP on lipid markers of oxidative 
damage and plasma lipophilic anti-oxidant levels before and after sleep.  
 
Methods:  We compared the effect of 8 weeks of therapeutic CPAP and sham 
CPAP, in a randomized cross-over study, on unesterified cholesterol, esterified 
unsaturated fatty acids (cholesteryl linoleate: C18:2, the major oxidizable lipid in LDL 
cholesterol, and cholesteryl arachidonate: C20:4), and their corresponding oxidized 
products (cholesteryl ester derived lipid hydroperoxides and hydroxides (CE-O(O)H) 
and Vitamin E (as α-tocopherol the most biologically active vitamin E form) in 
patients with moderate to severe OSA. All analytes were determined by liquid 
chromatography and concentrations determined by comparison to corresponding 
standard curves. Measurements were obtained prior to sleep, upon awakening and 2 
hours post awakening. Statistical analysis was performed using mixed effects 
models.  
 
Results: Amongst the 29 patients completing the study, three had incomplete data 
for part of a visit. The mean AHI, age and BMI were 38, 49 years and 32 kg/m2 
respectively. No differences in lipid based oxidative markers were observed between 
the CPAP and sham arms at any of the three time points (Unesterified cholesterol 
0.01, p=NS; cholesteryl linoleate: C18:2 0.05, p=NS; cholesteryl arachidonate: C20:4 
0.02, p=NS; lipid hydroperoxides and hydroxides (CE-O(O)H) -2.5, p=NS) and levels 
of the lipid-soluble antioxidant Vitamin E (0.03, p=NS). 
 
Conclusion:  
In this randomized sham-controlled trial, there was no change in lipid based 
oxidative markers or lipophilic antioxidant levels after 8 weeks of therapeutic CPAP 
compared with 8 weeks of sham CPAP.   
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INTRODUCTION 
 
Cardiovascular morbidity and mortality is increased in patients with obstructive sleep 
apnoea (OSA), an independent risk factor for hypertension and left ventricular 
diastolic dysfunction [1-4]. Population studies estimate that 2 and 4% of middle age 
women and men respectively, have OSA [5].  Postulated mechanisms linking chronic 
intermittent hypoxia and arousals in OSA with cardiovascular disease include 
transient episodes of hypertension, endothelial dysfunction and increased arterial 
stiffness, elevated sympathetic activity, intrathoracic pressures changes, 
inflammation and oxidative stress [6-11].   
 
Oxidative stress is characterized by an imbalance between oxidant-producing 
systems and antioxidant defence mechanisms, resulting in excessive formation of 
reactive oxygen species (ROS), chemically reactive by products of oxygen 
metabolism.  At lower levels, ROS participate in physiologic signalling pathways [12]. 
Detrimental modification of cell structures encompassing membranes, proteins, lipids 
and DNA, can occur when higher levels of ROS or reactive nitrogen species (RNS) 
are present. Oxidative modification of low-density lipoproteins (LDL) in the arterial 
wall is a key feature of atherogenesis [13]. A recently published population based 
study demonstrated an independent association between 10-year CAD events and 
plasma, oxidisable LDL level in a general population (Gomez et al, 2013 – not on 
pubmed yet). In OSA, the presence of increased oxidant molecules is further 
accompanied by reduced antioxidant capacity in OSA [14, 15]. 
 
Several randomized controlled trials in OSA have investigated the impact of 
continuous positive airway pressure (CPAP) on various oxidative markers. Lipid 
peroxidation markers utilized range from 8-isoprostane concentrations in plasma, 
urine and exhaled breath condensate as a reflection of airway lining fluid 
composition [16-18], to determination of malondialdehyde (MDA) in the thiobarbituric 
acid-reactive substance (TBARS) test, as an indirect method of assessment of lipid 
peroxidation [13, 19, 20]. Other oxidative markers measured include total levels of 
hydroperoxides [21] and nitrotyrosine, by product of tyrosine nitration mediated by 
RNS [22]. In addition, antioxidant protective enzyme paraxonase-1 (PON1) [13, 19, 
20], total antioxidant, vitamin A, E and gamma-glutamyltransferase levels (GGT) [23] 
have also been assessed as measures of antioxidant capacity in OSA. Most studies 
have shown a reduction in oxidative markers with CPAP. 
 
 
In a previously published study, improvements in postprandial triglycerides and total 
cholesterol were demonstrated with 8 weeks of CPAP use [24]. Here, we investigate 
the effect of CPAP on directly measured lipid markers of oxidative damage and 
plasma lipophilic anti-oxidant levels before and after sleep. 
 
 
 
METHODS 
 
Participants  
The protocol has previously been reported in a study which assessed the effect of 
CPAP treatment on postprandial lipidemia [24]. Details of randomization, allocation 
concealment and blinding and the flow of patients through the trial are included in the 
original report. Briefly, we recruited patients from sleep apnoea clinics who were 
aged > 21 years, with OSA severity in the upper moderate or severe range (Apnoea 
Hypopnoea Index or AHI ≥ 25) with a hypoxic component (Oxygen Desaturation 
Index or ODI ≥ 20). We excluded patients with BMI>35kg/m2, uncontrolled Type 2 
diabetes and patients who had previously used CPAP.  Other selection criteria are 
available on the Australian and New Zealand Clinical Trials Registry (ACTRN 
12605000066684 available at http://www.anzctr.org.au). The diagnosis of sleep 
apnoea was based on full overnight polysomnography in a clinical laboratory prior to 
recruitment. Apnoeas and hypopnoeas were scored using standard scoring 
techniques [25].  
 
Study design 
 
Patients who met the inclusion/exclusion criteria were randomized to receive CPAP 
(Remstar Auto, Phillips Respironics, USA) or sham CPAP each for 8 weeks in a 
crossover design with an intervening 1 month washout period between treatments 
(Figure 1). Sham CPAP devices are identical in appearance to the therapeutic 
devices except that the pressure delivered at the mask remains at 0.5 cmH2O, 
having no effect on sleep disordered breathing. In contrast, therapeutic CPAP was 
set to a pressure which prevented most sleep disordered breathing. This was 
determined during an at home pressure determination study as previously described 
[24]. Compliance data from both devices was obtained from machine downloads at 
the end of each treatment arm.  
 
Subjects did not change their exercise regime, diet or medications throughout the 
duration of the study. At predetermined times patients were fed breakfast, lunch and 
dinner as well as a snack in the mid-morning and mid-afternoon. The meals were 
representative of a standard western diet with a total energy of 9433kJ (30.5% fat, 
54.6% carbohydrate, 14.9% protein).  
 
Biochemical testing 
 
Biochemical measurements were obtained prior to sleep, upon awakening and 2 h 
post awakening. All analytes were determined by liquid chromatography and 
concentrations determined by comparison to corresponding standard curves. Paul to 
add details. 
 
Statistical Methods 
 
The final analyses included 29 patients who had completed the crossover trial, 
regardless of compliance with either therapeutic or sham CPAP.  Order effect was 
analysed using unpaired t-tests and main outcomes were analysed using mixed 
effects models. The treatment, order, time-point and treatment by time-point 
interaction were included as fixed effects and the patient was a random effect in all 
models. 
Data was analysed with the statistical software package SAS V.9.2 (SAS Institute) 
and StataTM version 10 (StataCorp, College Station, TX, USA).  
 
RESULTS 
 
	  A total of 29 patients completed the trial [24]. Three subjects had incomplete data for 
part of a visit. Nine participants withdrew or were withdrawn post randomization as 
previously reported [24]. 
 
Patient demographics, anthropometrics, diagnostic polysomnography data and 
baseline biochemistry data are as shown in table 1 and polysomnographic, CPAP 
compliance and residual AHI data obtained at the end of CPAP and sham treatment 
arms are outlined in table 2.  There was no significant difference observed in 
esterified cholesterol, unesterified cholesterol, lipid hydroperoxides and hydroxides 
or lipid soluble Vitamin E based on treatment modality or measurement time points –
Table 3). Log transformation of CEEOH was performed because...The ratio of 
oxidized substrates (CE-O(O)H) over total substrates (cholesterol esters) in CPAP 
versus Sham groups, did not demonstrate a significant difference (p=0.71) and 
neither was there a correlation between this ratio in CPAP users with AHI, minimum 
oxygen saturation, oxygen desaturation index (ODI) and arousals (r =0.14, r=0.16, r= 
0.18 and r = 0.01 respectively).  
 
There was no effect of compliant (>4 hours) versus non-compliant CPAP use on the 
baseline to CPAP change in oxidative parameters (p= .....for unesterified cholesterol, 
cholesteryl linoleate: C18:2, cholesteryl arachidonate: C20:4, lipid hydroperoxides 
and hydroxides (CE-O(O)H) and lipid-soluble antioxidant Vitamin E respectively. In 
addition, there was no effect of order of CPAP treatment on baseline to CPAP 
change in oxidative parameters.  
 
DISCUSSION 
 This is the first sham controlled randomized study to test the effect of CPAP 
treatment for OSA on directly measured lipid markers of oxidative stress. The study 
failed to demonstrate any beneficial influence of therapeutic CPAP compared to 
sham CPAP on unesterified cholesterol, a major potential atherogenic factor, 
esterified cholesterol, the bulk of oxidisable fat in lipoproteins, hydroperoxides and 
hydroxides (CE-O(O)H) and lipid soluble vitamin E, in subjects with moderate to 
severe obstructive sleep apnoea, irrespective of timing of measurements after 
daytime normoxia or nocturnal recurrent hypoxic episodes.  
 
A previous non-randomized 2 month intervention study with nasal CPAP in subjects 
with severe OSA demonstrated a significant reduction in overall oxidative stress as 
measured by morning total hydroperoxides and hydroxides (CE-O(O)H) levels, 
acutely after 1 night as well as 2 months of CPAP use [21]. Our study did not 
demonstrate an increase in cholesterol esters or substrate, nor a reduction in the 
end product of lipid-based oxidant damage. Total oxidative damage reflective of lipid, 
protein, membrane and deoxyribonucleic acid (DNA) peroxidation was measured in 
the Christou study compared with the isolated lipid based oxidative damage 
measured in our study.  This suggests that protein and DNA may be more 
susceptible to the hypoxia related oxidant damage of severe OSA and that CPAP 
may have more of an influence on non-lipid based oxidative markers. Potential 
differences in CPAP compliance and measurement techniques may also contribute 
to the differing results between studies.  
 
Several studies have utilized other common markers of lipid based peroxidation 
which include 8-isoprostane levels and the determination of malondialdehyde (MDA) 
in thiobarbituric acid-reactive substance (TBARS).  
 
A non-randomized study investigating the effect of CPAP on 8-isoprostane 
measured by exhaled breath analysis showed a beneficial effect [17]. A more recent 
12 week randomized controlled trial using 8-isoprostane concentrations in plasma, 
also showed a reduction in 8-isoprostane levels with CPAP use [16]. The accuracy, 
reliability and validity of 8-isoprostane measurements particularly when using 
commercial kits however, have been criticized [26-29].  Gas chromatography with 
mass-spectrometry detection, the gold standard, is laborious and costly, prohibiting 
its use in large epidemiological studies. As a result, enzyme linked immunosorbent 
assay (ELISA) is often used but is not felt to be comparable to the gold standard.  
 
Conflicting results have been demonstrated in non-randomized CPAP trials 
measuring MDA/TBARS levels. While some studies have shown a beneficial 
response to CPAP in patients with moderate to severe OSA after one night and up to 
1 year of CPAP use [13, 19, 20], others have not [30] . Similarly however, 
measurement of MDA/TBARS has been criticized for its inaccuracy and ambiguity 
[31].   
 
Reactive oxygen species are increased by several factors ranging from infection and 
inflammation to hypoxia related to OSA [32, 33]. The importance of further 
understanding the mechanistic link between various disease entities including 
atherosclerosis, and the recurrent OSA related hypoxia has lead to an abundance of 
basic science and clinical studies. Several antioxidant trials have also been 
published reflecting the reduced antioxidant capacity in OSA [15, 23, 34] and its 
partial resolution with CPAP [23]. Improvement in endothelial dysfunction has also 
been demonstrated in patients with OSA after administration of Vitamin C [35]. The 
lack of improvement in lipid soluble vitamin E levels in our study is in keeping with 
previously published data [23].  
 
There are several potential limitations to our study. Firstly, we did not repeat baseline 
biochemical testing after the washout period and hence assumed that any positive 
effect of CPAP on oxidative stress would revert to baseline levels after washout. The 
length of the washout period was long (4 weeks) however and we could not detect 
any order effect. Some studies showed a difference after 1-2 nights of CPAP 
suggesting that reversal of any effect from CPAP may be equally prompt [13, 17]. 
Secondly, our sham CPAP compliance was lower than therapeutic CPAP, although 
the difference was small (1 hour) and it would have been preferable to have longer 
nightly CPAP with both devices.  In addition, our study may not have been 
adequately powered to detect a difference in lipid based oxidative markers. Lastly, 
we did not measure non-lipid based oxidative stress markers including reactive 
nitrogen species mediated oxidative markers eg. nitrotyrosine. We focused on lipid 
only markers as altered lipid metabolism has been demonstrated in OSA and CPAP 
has been shown to decrease total cholesterol and triglycerides [24, 36].   
 
In summary, this is the first randomized sham controlled study investigating the 
influence CPAP on lipid-based oxidative markers over an 8 week period. No 
differences in unesterified cholesterol, esterified cholesterol, hydroperoxides and 
hydroxides and lipid soluble vitamin E levels were observed between the therapeutic 
and sham CPAP groups. This suggests that CPAP may have a greater influence on 
non-lipid based oxidative markers.  
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Figure 1 
 
Study Protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Unesterified cholesterol – need graphpad or other non-excel program to add SD  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
 
Cholesteryl linoleate (C18:2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
 
Cholesteryl arachidonate (C20:4)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 
 
Lipid hydroperoxides and hydroxides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 
 
Vitamin E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLES 
 
 
Table 1 
 
Patient demographic, anthropometric and baseline data  
 
 
Characteristics Mean ± SD 
 Demographics   
   Age (years) 49 ± 13 
   Male/Female (n) 28/1 
   BMI (kg.m-2) 31.6 ± 4.1 
 Sleep Apnoea   
   AHI (events/hr) 38.2 ± 24.3 
   ODI (events/hr) 31.5 ± 22.8 
   SaO2-T90 (%TST) 7.04 ± 11.4 
   Min SaO2 (%) 78.5 ± 11.1 
   Epworth Sleepiness Score (ESS) 10.1 ± 4.9 
 Medical History and Medication (n)   
   Hypertension 9 
   Type 2 Diabetes 2 
   Hypercholesterolemia 10 
   Antihypertensives 9 
   Oral hypoglycemics   
   Insulin   
   Statins 7 
 
 
AHI: Apnoea Hypopnoea Index; BMI: Body Mass Index; ODI: Oxygen Desaturation 
Index; SaO2-T90 (TST):  Percentage of Total Sleep Time spent with arterial oxygen 
saturation < 90%; Min SaO2 (%): Minimum arterial oxygen saturation. 
 
 
 
 
 
 
 
Table 2 
 
End of treatment polysomnography data  
 
Characteristics 
CPAP Sham   
Mean ± SD Mean ± SD P-value 
AHI (events/hr) 6.9 ± 11.0 40.0 ± 26.9 <0.00001 
ODI (events/hr) 5.1 ± 10 38.6 ± 21.7 <0.00001 
SaO2-T90 (%TST) 0.98 ± 2.3 9.7 ± 11.7 0.0004 
Min SaO2 (%) 89.1 ± 7.2 78.3 ± 8.4 <0.00001 
Treatment Compliance (hours/night) 4.6 ± 2.0? 3.4 ± 2.2? 0. 
 
AHI: Apnoea Hypopnoea Index; ODI: Oxygen Desaturation Index; SaO2-T90 (TST):  
Percentage of Total Sleep Time spent with arterial oxygen saturation < 90%; Min 
SaO2 (%): Minimum arterial oxygen saturation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
 
Effects of CPAP versus sham across all time points – using t-test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CPAP Sham 
Mean 
Difference 
P-
value 
(mean ± SD) (mean ± SD) 
 
  
Cholesterol (mM) 
	   	   	  
  
Unesterified  1.10 ± 0.37 1.11 ± 0.34 -0.02 0.86 
  
   
  
Esterified (mM) 
   
  
Cholesteryl linoleate: C18:2 1.12 ± 0.67 1.18 ± 0.67 -0.05 0.75 
Cholesteryl arachidonate: C20:4 0.17± 0.08 0.18 ± 0.09 -0.02 0.40 
  
	   	   	  
	  	  
Oxidized product (µM) 
	   	   	  
	  	  
Lipid hydroperoxides and 
hydroxides (CE-O(O)H)  20.74 ± 18.62 23.87 ± 19.03 -3.13 0.53 
  
   
  
Lipid Soluble Antioxidant (mM) 
   
  
Vitamin E (α-tocopherol)  9.72 ± 3.19 9.77 ± 3.72 0.05 0.95 
          
Table 4 
Effects of CPAP versus sham – Time point 1 (before sleep) using t-test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CPAP Sham 
Mean 
Difference 
P-
value 
(mean ± SD) (mean ± SD) 
 
  
Cholesterol (mM) 
	   	   	  
  
Unesterified  1.05 ± 0.33 1.10 ± 0.37 -0.05 0.61 
  
   
  
Esterified (mM) 
   
  
Cholesteryl linoleate: C18:2 1.09 ± 0.67 1.27 ± 0.80 -0.19 0.34 
Cholesteryl arachidonate: C20:4 0.17± 0.08 0.20 ± 0.01 -0.03 0.25 
  
	   	   	  
	  	  
Oxidized product (µM) 
	   	   	  
	  	  
Lipid hydroperoxides and 
hydroxides (CE-O(O)H)  19.62 ± 24.18 24.23 ± 24.13 -4.61 0.48 
  
   
  
Lipid Soluble Antioxidant (mM) 
   
  
Vitamin E (α-tocopherol)  9.21 ± 3.03 8.59 ± 4.05 0.62 0.51 
          
Table 5 
Effects of CPAP versus sham – Time point 2 (After sleep) using t-test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CPAP Sham 
Mean 
Difference 
P-
value 
(mean ± SD) (mean ± SD) 
 
  
Cholesterol (mM) 
	   	   	  
  
Unesterified  1.13 ± 0.37 1.14 ± 0.37 -0.01 0.89 
  
   
  
Esterified (mM) 
   
  
Cholesteryl linoleate: C18:2 1.23 ± 0.84 1.13 ± 0.65 0.10 0.64 
Cholesteryl arachidonate: C20:4 0.18 ± 0.10 0.19 ± 0.01 -0.01 0.80 
  
	   	   	  
	  	  
Oxidized product (µM) 
	   	   	  
	  	  
Lipid hydroperoxides and 
hydroxides (CE-O(O)H)  19.13 ± 19.80 22.96 ± 23.36 -3.82 0.52 
  
   
  
Lipid Soluble Antioxidant (mM) 
   
  
Vitamin E (α-tocopherol)  10.07 ± 3.58 10.79 ± 4.71 -0.72 0.52 
          
Table 6 
Effects of CPAP versus sham – Time point 3 (2 hours post sleep) using t-test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CPAP Sham 
Mean 
Difference 
P-
value 
(mean ± SD) (mean ± SD) 
 
  
Cholesterol (mM) 
	   	   	  
  
Unesterified  1.13 ± 0.49 1.10 ± 0.07 -0.02 0.83 
  
   
  
Esterified (mM) 
   
  
Cholesteryl linoleate: C18:2 1.05 ± 0.70 1.13 ± 0.65 -0.10 0.59 
Cholesteryl arachidonate: C20:4 0.16 ± 0.07 0.17 ± 0.07 -0.01 0.52 
  
	   	   	  
	  	  
Oxidized product (µM) 
	   	   	  
	  	  
Lipid hydroperoxides and 
hydroxides (CE-O(O)H)  24.78 ± 23.02 24.87 ± 22.19 -0.10 0.98 
  
   
  
Lipid Soluble Antioxidant (mM) 
   
  
Vitamin E (α-tocopherol)  10.07 ± 3.58 10.79 ± 4.71 -0.72 0.52 
          
